SCHEMBL3862402

SCHEMBL3862402

CCCC(=O)COc1ccc(CCC(=O)NN)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PLA2G4B P0C869 1/20 0.47
POLB P06746 2/20 0.45
CYP2C19 P33261 2/20 0.45
F2RL1 P55085 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HIF1A Q16665 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CTSD P07339 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3862543 0.90 KMT2A (0.49) GAAMEN1KMT2ALMNAL3MBTL1
SCHEMBL3864591 0.84 KMT2A (0.51) GAAMEN1KMT2ALMNAL3MBTL1
SCHEMBL4411258 0.84 MAPT (0.54) GAAMEN1KMT2ALMNAL3MBTL1
SCHEMBL6538553 0.81 S1PR4 (0.57) LMNAL3MBTL1PLA2G4BCYP1A2CYP2D6
SCHEMBL13903016 0.77 ALDH1A1 (0.67) MEN1KMT2AL3MBTL1POLBF2RL1
SCHEMBL4409663 0.77 FFAR1 (0.56) GAALMNAPOLBCYP2C19F2RL1
SCHEMBL3861180 0.76 ALDH1A1 (0.51) MEN1KMT2ALMNAL3MBTL1POLB
SCHEMBL9704119 0.74 HDAC2 (0.51) GAAL3MBTL1CYP2C19CYP1A2CYP3A4
SCHEMBL16576414 0.74 GAA (0.50) GAAKMT2APOLBCYP2C19F2RL1
SCHEMBL4416871 0.73 FFAR1 (0.51) POLBCYP2C19F2RL1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253166-A1 Conjugation of Peptides NOVO NORDISK A/S (DK) 2009-10-08 US claimed
US-20070111926-A1 Conjugation of peptides NOVO NORDISK A/S (DK) 2007-05-17 US claimed
EP-1673464-A2 CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2006-06-28 EP claimed
WO-2005035553-A2 CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2005-04-21 WO claimed
US-20090253166-A1 Conjugation of Peptides NOVO NORDISK A/S (DK) 2009-10-08 US disclosed
US-20090176967-A1 Conjugation of FVII NOVO NORDISK HEALTHCARE A/G (CH) 2009-07-09 US disclosed
US-7524813-B2 Selectively conjugated peptides and methods of making the same NOVO NORDISK HEALTH CARE AG (CH) 2009-04-28 US disclosed
US-20070111926-A1 Conjugation of peptides NOVO NORDISK A/S (DK) 2007-05-17 US disclosed
EP-1778838-A2 CONJUGATION OF FVII Novo Nordisk Health Care AG (CH) 2007-05-02 EP disclosed
EP-1673464-A2 CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2006-06-28 EP disclosed
WO-2006013202-A2 CONJUGATION OF FVII NOVO NORDISK HEALTH CARE AG (DK) 2006-02-09 WO disclosed
WO-2005035553-A2 CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176967-A1 Conjugation of FVII F13B, F13A1, FGB GAA 3379/4885MEN1 2945/4885KMT2A 3202/4885
US-20070111926-A1 Conjugation of peptides DNPEP, ENPEP, ANPEP GAA 426/4885MEN1 1266/4885KMT2A 2475/4885
US-20090253166-A1 Conjugation of Peptides DNPEP, ENPEP, ANPEP GAA 426/4885MEN1 1266/4885KMT2A 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.